Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(01): 011-015
DOI: 10.1055/s-0041-1733817
Original Article

An Immunoassay for Human Chorionic Gonadotropin in Cerebrospinal Fluid: Validation of a Modified-Approved Method for Accreditation by the College of American Pathologists

Yao Hu‡   *
1   Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
,
Jiajin Ni‡   *
2   Department of Nursing, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
,
Huating Zhang
1   Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
,
Wenqing Wu
1   Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
,
Yanwen Chen
1   Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
,
Ming Guan
1   Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
› Author Affiliations Funding This study was supported by grants from the Shanghai Medical and Health Development Foundation.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Human chorionic gonadotropin (hCG) detection in cerebrospinal fluid (CSF) can provide additional value in the diagnosis of germinoma. However, matrix effects can influence the results when alternative sample types are used. Therefore, modified-cleared/approved methods, which are standard methods used outside their intended scope, are of interest. The aim of the present study was to establish a model to validate modified-approved methods in agreement with the College of American Pathologists (CAP) accreditation requirements.

Methods Concentrations of hCG in CSF were determined by means of electrochemiluminescence immunoassay using a Roche Cobas e 602 immunoassay analyzer. Based on the intended use, the following performance characteristics were evaluated: precision, the limit of quantitation (LoQ), and the analytical measurement range (AMR). The reference interval (RI) was also established. For the clinical application study, CSF and serum hCG were measured in 10 patients diagnosed with germinoma.

Results The intra- and inter-assay precisions at two levels (10, 250 IU/L) were 0.64 and 0.57% and 4.26 and 3.54%, respectively. The LoQ for hCG was determined to be 0.25 IU/L. The AMR was set from 0.2 to 1,200 IU/L. The RI for hCG in CSF was below 0.40 IU/L. The CSF hCG levels of 10 patients were all above 0.4 IU/L before therapy.

Conclusion Modified-approved methods were validated and showed that the quality specifications of the medical laboratory have a positive value in the clinical context. The illustration of quantification of hCG in CSF resulted in compliance with the CAP accreditation requirements.

Keywords

human chorionic gonadotropin - cerebral spinal fluid - method validation

Authors' Contributions

All authors have accepted the responsibility for the entire content of this submitted manuscript and approved submission.


Ethics Approval

This study was approved by the Ethics Committee of Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China (protocol KY-2016–395). All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.


* Yao Hu and Jiajin Ni contributed equally to this work.




Publication History

Article published online:
08 September 2021

© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131 (06) 803-820
    Google Scholar
  • 2 Echevarría ME, Fangusaro J, Goldman S. Pediatric central nervous system germ cell tumors: a review. Oncologist 2008; 13 (06) 690-699
    Google Scholar
  • 3 Matsutani M, Sano K, Takakura K. et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 1997; 86 (03) 446-455
    Google Scholar
  • 4 Wong TT, Chen YW, Guo WY, Chang KP, Ho DM, Yen SH. Germinoma involving the basal ganglia in children. Childs Nerv Syst 2008; 24 (01) 71-78
    CrossrefPubMedGoogle Scholar
  • 5 Jubran RF, Finlay J. Central nervous system germ cell tumors: controversies in diagnosis and treatment. Oncology (Williston Park 2005; 19 (06) 705-711 , discussion 711–712, 715–717, 721
    PubMedGoogle Scholar
  • 6 Ferguson AM, Ford B, Gronowski AM. Method validation for cerebral spinal fluid human chorionic gonadotropin measurement with the Advia Centaur. Clin Chem 2008; 54 (08) 1408-1409
    CrossrefPubMedGoogle Scholar
  • 7 Hu M, Guan H, Lau CC. et al. An update on the clinical diagnostic value of β-hCG and αFP for intracranial germ cell tumors. Eur J Med Res 2016; 21: 10
    CrossrefPubMedGoogle Scholar
  • 8 Clinical and Laboratory Standards Institute (CLSI). Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach, Approved Guideline. CLSI document EP06-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2003
    Google Scholar
  • 9 Mitsios JV, McClellan A, Brown S, Gronowski AM. Human chorionic gonadotropin and α-fetoprotein in cerebral spinal fluid: method validation and retrospective review. Clin Biochem 2014; 47 (7-8) 632-635
    CrossrefPubMedGoogle Scholar
  • 10 Tian C, Shi Q, Pu C. et al. Re-evaluation of the significance of cerebrospinal fluid human chorionic gonadotropin in detecting intracranial ectopic germinomas. J Clin Neurosci 2011; 18 (02) 223-226
    CrossrefPubMedGoogle Scholar
  • 11 Stöckl D, D'Hondt H, Thienpont LM. Method validation across the disciplines—critical investigation of major validation criteria and associated experimental protocols. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877 (23) 2180-2190
    CrossrefPubMedGoogle Scholar
  • 12 Nordin G, Dybkaer R, Forsum U, Fuentes-Arderiu X, Schadow G, Pontet F. IFCC-IUPAC Committee on Nomenclature, Properties, and Units (C-NPU). An outline for a vocabulary of nominal properties and examinations–basic and general concepts and associated terms. Clin Chem Lab Med 2010; 48 (11) 1553-1566
    CrossrefPubMedGoogle Scholar
  • 13 González-Sánchez V, Moreno-Pérez O, Pellicer PS. et al. Validation of the human chorionic gonadotropin immunoassay in cerebrospinal fluid for the diagnostic work-up of neurohypophyseal germinomas. Ann Clin Biochem 2011; 48 (Pt 5) 433-437
    CrossrefPubMedGoogle Scholar